ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,995.54
0.38%
US Tech 100
20,557.20
0.08%
Dow Jones
43,988.99
0.59%
Brent Oil
73.885
-2.09%
Bitcoin
76,526.26
0.83%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Windtree Therapeutics Inc (WINT)

  7. Windtree Therapeutics Inc (WINT) News

Windtree Therapeutics Inc

Windtree Therapeutics Inc (WINT)

NASDAQ
0.585
-0.0257
(-4.21%)
At close: November 08 4:00PM
Delayed by 15 minutes
0.5801
-0.0049
( -0.84% )
After Hours: 4:56PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

WINT News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
October 09 2024
WINT (-4.21%)

Form 8-K - Current report
Edgar (US Regulatory)
September 25 2024
WINT (-4.21%)

Form 8-K - Current report
Edgar (US Regulatory)
September 24 2024
WINT (-4.21%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
September 04 2024
WINT (-4.21%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
September 04 2024
WINT (-4.21%)

WINT Discussion

View Posts
Mr. Zen Mr. Zen 3 days ago
Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.
👍️0
tw0122 tw0122 2 weeks ago
Ping pong .80s to $1s
👍️0
Mr. Zen Mr. Zen 3 weeks ago
This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO
👍 1
glenn1919 glenn1919 3 weeks ago
WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 weeks ago
WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s
👍️0
tw0122 tw0122 3 weeks ago
1.11 test again
👍️0
tw0122 tw0122 3 weeks ago
WINT $1.11 breakout solid and $1.44
Up next 3m floater
👍️0
Mr. Zen Mr. Zen 3 weeks ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
👍️0
Monksdream Monksdream 4 weeks ago
WINT new 52 week low
👍️0
Monksdream Monksdream 1 month ago
WINT new 52=week low
👍️0
Roadtojourney Roadtojourney 1 month ago
Yup they pr only to dilute there share pos?? Imo
👍️0
Mr. Zen Mr. Zen 1 month ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.
👍️0
tw0122 tw0122 1 month ago
$1.26 + 36%
👍️0
tw0122 tw0122 1 month ago
Pump it
👍️0
Monksdream Monksdream 1 month ago
WINT anew 52 week low
👍️0
Monksdream Monksdream 1 month ago
WINT under $2
👍️0
Mr. Zen Mr. Zen 1 month ago
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
👍️0
Monksdream Monksdream 1 month ago
WINT new 52 week low
👍️0
Awl416 Awl416 1 month ago

On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
👍️0
glenn1919 glenn1919 2 months ago
WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
na na na na 2 months ago
There's a big borrowing fee. 50 dollars in losses per 1000 dollars of shorted shares per day.
👍️0
tw0122 tw0122 2 months ago
FOR RESALE OF UP TO 27.7 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: Further company coverage:

Wow!!
👍️0
tw0122 tw0122 2 months ago
My bad 10 million shares offering announced recently this won’t go anywhere. Share selling machine short it
👍️0
tw0122 tw0122 2 months ago
Pop it to $5 already another 400k floater $3.85 resistance watch
👍️0
Awl416 Awl416 2 months ago
Don’t blink
👍️0
na na na na 2 months ago
If you short 1000 dollars of shares you're now paying 70 dollars a day in fees,Up from 50 dollars of fees a few days ago.




👍️0
na na na na 2 months ago
Jumped from 700 percent to 800 percent borrow fee.

👍️0
Anite Anite 2 months ago
For the upcoming trading day on Friday, 6th we expect Windtree Therapeutics Inc to open at $3.05 and during the day (based on 14 day Average True Range), to move between $3.10 and $4.75, which gives a possible trading interval (+/-54.61%) up from last closing price. If Windtree Therapeutics Inc takes out the full calculated possible swing range there will be an estimated 109.21% move between the lowest and the highest trading price during the day.
👍️0
Anite Anite 2 months ago
Last week:First, the private placement delivers needed capital to support company operations, including the active Phase 2b clinical trial for istaroxime in cardiogenic shock. Second, the transaction fully converted and eliminated senior notes, including senior secured notes we used as bridge financing over the past several months eliminating this debt from our balance sheet.” 
Windtree shares are blasting higher on heavy volume Friday with more than 9 million shares
👍️0
Anite Anite 2 months ago
Borrow rates now 1500%!!!!!
🚀 1
Mr. Zen Mr. Zen 2 months ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.

Istaroxime is a novel first-in-class therapy that has demonstrated the ability to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function in patients with compromised cardiac function in three positive Phase 2 trials enrolling patients with acute heart failure (AHF). Cardiogenic shock is a serious condition that can occur when AHF patients continue to deteriorate and the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Mortality rates are significant and, depending on severity, range from 7% to 40% in the U.S. There is a lack of satisfactory pharmacological intervention to reverse the condition as available therapies have unwanted side effects such as risk for arrhythmias, decreased blood pressure, and renal dysfunction that limit their usefulness and position them as “rescue medicines” for severe cases. The cardiogenic shock worldwide total market value is estimated to be $1.25 billion per year.
👍️0
na na na na 2 months ago
RIP SHORTS! 50 dollars per 1000 dollars of share fee.
👍️0
na na na na 2 months ago
👍️0
Awl416 Awl416 2 months ago
Oh cmon
👍️0
na na na na 2 months ago
SQUEEZE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

700 percent borrowing rate!!!


If you short 1000 dollars of stock you pay a fee of 52 dollars a day!

🚀 1
willlbone willlbone 2 months ago
Get up and go, got up and WINT.
👍️0
na na na na 2 months ago
Buy the dip!!

👍️0
TIMGZ TIMGZ 3 months ago
WHAAAAT**** LARGEST SHORT INTEREST****44%
👍️0
Monksdream Monksdream 3 months ago
WINT 10Q due AUGUST 20
👍️0
Awl416 Awl416 3 months ago
Watch out
👍️0
Awl416 Awl416 3 months ago
Quite the close
👍️0
Monksdream Monksdream 3 months ago
WINT under $9
👍️0
Zardiw Zardiw 3 months ago
$WINT +200% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z
👍️0
PaladinOcean33 PaladinOcean33 3 months ago
WINT 4.40s
👍️0
Mr. Zen Mr. Zen 3 months ago
That is what phase three trials are all about, do not expect much for another 6 to 9 months. Then it is either break out or bust, dig into it a bit.
👍️0
Luckysevens Luckysevens 3 months ago
“They just have to prove it” yeah thats the problem lolz
👍️0
peterus peterus 3 months ago
relax bro i will do some dd
👍️0
Mr. Zen Mr. Zen 3 months ago
no do some research here,they have a product that works they just have to prove it. Its call [phase three results, God I am so tired of these mouthy kids on this site
👍️0
peterus peterus 3 months ago
$30 YES after R/S
👍️0
Mr. Zen Mr. Zen 3 months ago
The monster run will happen, but not before phase 3 trials are released or a buyout happens, holding and looking for $30. a share plus
👍️0

Your Recent History

NASDAQ
WINT
Windtree Therapeutics
USOTC
LVVV
Livewire Ergogenics (PK)
AMEX
JVAL
Jpmorgan US Value Factor...
KOSDAQ
3156401D
8r
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved